Focus On J&J, Pfizer COVID-19 Vaccine Pricing As India Permits Private Sales

COVAX, Other Contracts Could Provide Hints

Prices for J&J and Pfizer’s COVID-19 vaccines will be watched closely as India permits private sales. While demand is set to spike with age criteria for those eligible to receive the shots expanded, local manufacturers Serum Institute and Bharat Biotech are ramping up capacities with the government’s help.

Money bag with the word Covid-19 and government building on the scales. State support for infected and sick people. Financial help. Insurance. Coronavirus pandemic infection. Healthcare, medicine.
The Indian Government Has Freed Pricing and Provided Funding For COVID-19 Vaccines • Source: Shutterstock

Following India’s decision to permit private sales of COVID-19 vaccines from 1 May, all eyes are on companies including Johnson & Johnson and Pfizer Inc., which have been keen to introduce their vaccines but perhaps not at the INR150-200 ($2-2.70) that domestic manufacturers Serum Institute of India Pvt. Ltd. and Bharat Biotech have offered for the government’s immunization program.

With an announcement on 19 April that SARS-CoV-2 vaccine manufacturers can sell 50% of their monthly supplies to the federal...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia